Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Cash & Equivalents data on file, last reported at $188.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 1.5% year-over-year to $188.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.5 million (up 1.5% YoY) and the FY2025 annual result came in at $226.5 million, up 120.62% from the prior year.
• Cash & Equivalents slipped to $188.5 million in Q1 2026, from $201.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $226.5 million in Q3 2025 to a low of $53.9 million in Q4 2024.
• A 5-year average of $131.3 million and a median of $127.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 76.8% — and 2025, when it jumped 274.18%.
• Tracing ARWR's Cash & Equivalents over 5 years: stood at $202.2 million in 2022, then plunged by 71.22% to $58.2 million in 2023, then retreated by 7.43% to $53.9 million in 2024, then jumped by 274.18% to $201.6 million in 2025, then fell by 6.52% to $188.5 million in 2026.
• The last three Cash & Equivalents figures came in at $188.5 million (Q1 2026), $201.6 million (Q4 2025), and $226.5 million (Q3 2025), per Business Quant data.